Misoprostol for prevention and treatment of postpartum haemorrhage : a systematic review

dc.contributor.authorOlefile, Kabelo M.
dc.contributor.authorKhondowe, Oswell
dc.contributor.authorM'Rithaa, Doreen
dc.identifier.citationOlefile, K.M., Khondowe, O. & M’Rithaa, D. 2013. Misoprostol for prevention and treatment of postpartum haemorrhage: a systematic review. Curationis, 36(1), doi:10.4102/curationis.36i1.57.en_ZA
dc.identifier.issn0379-8577 (print)
dc.identifier.issn2223-6279 (online)
dc.descriptionPublication of this article was funded by the Stellenbosch University Open Access Fund.en_ZA
dc.descriptionThe original publication is available at
dc.description.abstractBackground: Postpartum haemorrhage (PPH) is a leading cause of maternal mortality especially in the developing world. Misoprostol, a highly effective drug is highly effective in inducing uterine contractions and has been proposed as a low-cost, easy-to-use intervention for PPH. Objective: This study assessed evidence of the effectiveness of misoprostol for the prevention and treatment of PPH. Method: Databases searched included MEDLINE, PUBMED, CINHAL, Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE. Reference lists and conference proceedings were also searched for more studies. Three studies included in the meta-analysis were limited to randomised controlled trials (RCT). Two reviewers independently screened all articles for methodological quality using a standardised instrument adapted from the Cochrane Collaboration website. Data were entered in Review Manager 5.1 software for analysis. Results: Three trials (n = 2346) compared misoprostol to a placebo. Misoprostol was shown not to be effective in reducing PPH (risk ratios [RR] 0.65; 95% confidence interval [CI] 0.40–1.06). Only one trial reported on the need for a blood transfusion (RR 0.14; 95% CI 0.02–1.15). Shivering (RR 2.75; 95% CI 2.26–3.34) and pyrexia (RR 5.34; 95% CI 2.86–9.96) were significantly more common with misoprostol than with a placebo. Conclusion: The use of misoprostol was not associated with any significant reduction in the incidence of PPH. Therefore, in order to verify the efficacious use of misoprostol in the treatment of PPH, specialised investigations of its dose and routes of administration for clinically significant effects and acceptable side effects are warranted.en_ZA
dc.description.sponsorshipStellenbosch Universityen_ZA
dc.format.extent10 p.
dc.publisherAOSIS Open Journalsen_ZA
dc.subjectPostpartum hemorrhageen_ZA
dc.subjectUterine hemorrhageen_ZA
dc.subjectLabor (Obstetrics) -- Complicationsen_ZA
dc.subjectRandomized controlled trialsen_ZA
dc.titleMisoprostol for prevention and treatment of postpartum haemorrhage : a systematic reviewen_ZA
dc.description.versionPublishers' versionen_ZA
dc.rights.holderAuthors retain copyrighten_ZA

Files in this item


This item appears in the following Collection(s)